Saillant Therapeutics B.V.

https://www.saillanttherapeutics.nl

LinkedIn: https://www.linkedin.com/company/saillant-therapeutics

Saillant Therapeutics, established in 2018 by Dr. Hamid el Azzouzi and Dr. Ad van Gorp, and recently joined by Dr. Joost van Bree as CEO, leverages its expertise in preclinical drug development to further validate and develop the promising therapeutic strategy of its ST-01 platform against acute ischemic stroke, heart failure (HF), Alzheimer’s disease and viral infections in general. ST-01 activates a cellular master regulator, thus controlling adaptive functions in various cells and tissues. Therapeutic intervention through this regulator mechanism enables the prevention of tissue damage to vital organ systems such as the cardiovascular system and the central nervous system. The same mechanism also effectively inhibits intracellular virus replication. Saillant Therapeutics has a product pipeline covering novel compounds of which three therapeutic leads were selected. To date, seed financing has enabled the preclinical development and validation of the ST-01 analogs. It is the ambition of Saillant to advance its ST-01 platform also towards a variety of applications, resulting in at least one lead drug candidate reaching the clinic before the end of 2022. *

	Start	2018-01-01 established
	Industry	drug development
	Person	van Bree, Joost (Saillant Therapeutics 202008 CEO before Pepscan 200803–200911 CEO resigned 12/09)
	Person 2	van Gorp, Ad (Cytura Therapeutics 201903– CEO + Co-Founder before Lead Pharma 201502 CEO + Co-founder)

	Region	Nijmegen
	Country	Netherlands
	Street	7 Transistorweg
	City	6534 AT Nijmegen
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Saillant Therapeutics B.V.. (8/11/20). "Press Release: Dutch Saillant Therapeutics to Develop Generic Virus Inhibiting Therapy Based on Activation of a Cellular Master Regulator, Ending Virus Replication". Nijmegen.

		Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Saillant Therapeutics B.V.

[1] Saillant Therapeutics B.V.. (8/11/20). "Press Release: Dutch Saillant Therapeutics to Develop Generic Virus Inhibiting Therapy Based on Activation of a Cellular Master Regulator, Ending Virus Replication". Nijmegen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]